Author:
Phillips Andrew N,Leen Clifford,Wilson Alan,Anderson Jane,Dunn David,Schwenk Achim,Orkin Chloe,Hill Teresa,Fisher Martin,Walsh John,Pillay Deenan,Bansi Loveleen,Gazzard Brian,Easterbrook Philippa,Gilson Richard,Johnson Margaret,Sabin Caroline A
Reference20 articles.
1. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes;Ledergerber;Lancet,2004
2. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group;Mocroft;J Infect Dis,2004
3. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals;Lohse;AIDS,2005
4. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia;Lazzarin;N Engl J Med,2003
5. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor in patients with triple class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections. Feb 25–28, 2007, Los Angeles, CA, USA. Abstract 105aLB.
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献